Zentalis Pharmaceuticals (ZNTL) Stock: Buy, Sell, or Hold?
ZNTL - Zentalis Pharmaceuticals, Inc. Common Stock
$2.21
-0.20 (-8.30%)
▼
5d:
+3.76%
30d:
-19.64%
90d:
-51.0%
BUY
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When ZNTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZNTL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ZNTL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ZNTL is currently trading at $2.21, which is considered slightly low relative to its 30-day fair value range of $2.37 to $3.01.
Technical Outlook: Technically, ZNTL is in a strong downtrend. Immediate support is located at $2.07, while resistance sits at $2.64. Short-term momentum is weak, with the stock down 8.3% recently.
Market Sentiment: ZNTL scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.52 (+240.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZNTL is in a strong downtrend. Immediate support is located at $2.07, while resistance sits at $2.64. Short-term momentum is weak, with the stock down 8.3% recently.
Market Sentiment: ZNTL scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $7.52 (+240.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.37 -
$3.01
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.3%)
- BULLISH: Trading 240.4% below Wall St target ($7.52)
- BULLISH: Bottoming setup score 69/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$2.37 -
$3.01
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.07
Resistance Level
$2.64
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.25
Wall Street Target
$7.52
(+240.4%)
Share & Embed Analysis
Last updated: October 23, 2026 6:35 PM ET
Data refreshes hourly during market hours. Next update: 7:35 PM
Data refreshes hourly during market hours. Next update: 7:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZNTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 47 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$153 | 59 HOLD |
